| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Lin Xu | |
| Jing Gao | |||
| Dongmei Meng | |||
| Anmu Xie | |||
| P2860 | cites work | Tau-aggregation inhibitor therapy for Alzheimer's disease | Q22252512 |
| Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system | Q27010627 | ||
| Role of redox signaling in neuroinflammation and neurodegenerative diseases | Q27012569 | ||
| Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons | Q27332460 | ||
| Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease | Q28280353 | ||
| Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease | Q28285170 | ||
| Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx | Q28572481 | ||
| Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria | Q29614408 | ||
| Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease | Q30054419 | ||
| L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. | Q33412141 | ||
| Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease | Q33666297 | ||
| Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease | Q50553843 | ||
| Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein | Q73367962 | ||
| Paraoxonase 1 Met--Leu 54 polymorphism is associated with Parkinson's disease | Q73589452 | ||
| Etiology and pathogenesis of Parkinson's disease | Q84231134 | ||
| Oxidative stress induces intralysosomal accumulation of Alzheimer amyloid beta-protein in cultured neuroblastoma cells | Q40262429 | ||
| Superoxide dismutase 1 modulates expression of transferrin receptor. | Q40282739 | ||
| Mitochondrial complex I deficiency in Parkinson's disease | Q41821730 | ||
| Preferential selectivity of inhibitors with human tau protein kinase gsk3β elucidates their potential roles for off-target Alzheimer's therapy | Q42263333 | ||
| Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk | Q42612701 | ||
| Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease | Q43242111 | ||
| Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging | Q43509556 | ||
| Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. | Q44113530 | ||
| Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease | Q44125044 | ||
| Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease | Q46186292 | ||
| Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. | Q46890602 | ||
| Characterization of metal profiles in serum during the progression of Alzheimer's disease | Q46958881 | ||
| Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia | Q47989626 | ||
| Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology | Q48422549 | ||
| Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years | Q48835886 | ||
| ??? | Q64781356 | ||
| The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen | Q33790013 | ||
| Alpha-synuclein, Parkinson's disease, and Alzheimer's disease | Q34316503 | ||
| Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice | Q34430592 | ||
| Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases | Q34495097 | ||
| Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease | Q34572608 | ||
| Neuroprotective strategies involving ROS in Alzheimer disease | Q34757939 | ||
| Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. | Q34760606 | ||
| Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy | Q34964783 | ||
| The locus ceruleus norepinephrine system: functional organization and potential clinical significance | Q35013227 | ||
| Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review | Q35074055 | ||
| Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease | Q35083125 | ||
| Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. | Q35788235 | ||
| Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications | Q36086872 | ||
| Cognitive decline correlates with neuropathological stage in Parkinson's disease | Q36524967 | ||
| Nicotinic receptors in neurodegeneration | Q36828916 | ||
| Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease | Q36985218 | ||
| α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment | Q37086400 | ||
| Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. | Q37201727 | ||
| Levodopa unresponsive symptoms in Parkinson disease | Q37264473 | ||
| The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease | Q37485028 | ||
| Activated astroglia during chronic inflammation in Alzheimer's disease--do they neglect their neurosupportive roles? | Q37596067 | ||
| The nonmotor symptoms of Parkinson's disease--an overview | Q37699207 | ||
| Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities | Q37851523 | ||
| Alzheimer's pathogenesis: is there neuron-to-neuron propagation? | Q37868480 | ||
| Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. | Q37947588 | ||
| Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. | Q37961898 | ||
| Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases | Q38010262 | ||
| Oxidative stress in genetic mouse models of Parkinson's disease | Q38029327 | ||
| Advances in the mechanisms of Parkinson's disease. | Q38078568 | ||
| CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls | Q38145962 | ||
| The neuropathology of neurodegeneration with brain iron accumulation | Q38161017 | ||
| The oxidative stress hypothesis in Alzheimer's disease | Q38163767 | ||
| In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals | Q38195938 | ||
| A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death | Q38368071 | ||
| Cognitive and neuropathologic correlates of Stroop Color-Word Test performance in Alzheimer's disease | Q38433214 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| Parkinson's disease | Q11085 | ||
| neurodegeneration | Q1755122 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 648740 | |
| P577 | publication date | 2014-05-12 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease | |
| P478 | volume | 2014 |
| Q51129501 | Association of IGF1 gene polymorphism with Parkinson's disease in a Han Chinese population. |
| Q40135749 | Association of Parkinson's Disease GWAS-Linked Loci with Alzheimer's Disease in Han Chinese |
| Q30952223 | Comparative Meta-Analysis of Transcriptomics Data during Cellular Senescence and In Vivo Tissue Ageing |
| Q33734563 | Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology |
| Q57040576 | Endothelins in inflammatory neurological diseases |
| Q92316611 | Evaluation of the Common Molecular Basis in Alzheimer's and Parkinson's Diseases |
| Q38451584 | Functional genomics of candidate genes derived from genome-wide association studies for five common neurological diseases. |
| Q64090577 | Gene expression meta-analysis of Parkinson's disease and its relationship with Alzheimer's disease |
| Q90604684 | Genetic networks in Parkinson's and Alzheimer's disease |
| Q60916457 | Identification of Blood Biomarkers for Alzheimer's Disease Through Computational Prediction and Experimental Validation |
| Q92164026 | Impact of CHRNA5 polymorphisms on the risk of schizophrenia in the Chinese Han population |
| Q36893571 | Impact of maternal cigarette smoke exposure on brain inflammation and oxidative stress in male mice offspring |
| Q35507433 | Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. |
| Q35771313 | Longitudinal study of normal cognition in Parkinson disease |
| Q36386690 | Low-Dose Aronia melanocarpa Concentrate Attenuates Paraquat-Induced Neurotoxicity. |
| Q42368069 | Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model |
| Q47099182 | Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway |
| Q52734704 | Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model. |
| Q47117694 | Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes |
| Q35710568 | Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: A review. |
| Q89879475 | PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape |
| Q36789528 | Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer |
| Q90312509 | PhIP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease |
| Q39205712 | Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease |
| Q26738450 | Putative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's Disease |
| Q39474606 | Reactive oxygen species-mediated neurodegeneration is independent of the ryanodine receptor in Caernorhabditis elegans |
| Q64118653 | Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review |
| Q47115262 | Subcellular analysis of pigeon hair cells implicates vesicular trafficking in cuticulosome formation and maintenance |
| Q96136881 | T1-weighted MRI-driven Brain Age Estimation in Alzheimer's Disease and Parkinson's Disease |
| Q48092663 | Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders. |
| Q36932291 | Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report. |
| Q90671795 | What and How Can Physical Activity Prevention Function on Parkinson's Disease? |
Search more.